Literature DB >> 3067540

Rating scales for mood disorders: applicability, consistency and construct validity.

P Bech1.   

Abstract

Rating scales for mood disorders have been reviewed with special reference to their consistency, applicability, and validity. Diagnostic scales with a biometric reference to antidepressants have been developed on the basis of the Newcastle Scales. This Diagnostic Melancholia Scale (DMS) includes two dimensions, one measuring endogenous depression, and one measuring reactive depression. These dimensions were found not to be mutually exclusive as 30% of the depressed patients scored high on both dimensions. Scales measuring outcomes of treatment were subdivided into (a) scales measuring disability of clinical depression (melancholia), anxiety, and mania, (b) scales measuring distress as a construct of side-effects during treatment, and (c) scales measuring discomfort or quality of life. Disability, distress and discomfort should be separately validated as they reflect different aspects of outcome of treatment. Self-rating scales have their main applicability in the measurement of discomfort.

Entities:  

Mesh:

Year:  1988        PMID: 3067540     DOI: 10.1111/j.1600-0447.1988.tb08567.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  15 in total

1.  The economics of an intensive education programme for asthmatic patients: a prospective controlled trial.

Authors:  B Søondergaard; F Davidsen; B Kirkeby; M Rasmussen; H Hey
Journal:  Pharmacoeconomics       Date:  1992-03       Impact factor: 4.981

2.  Suicidality in Bipolar Disorder: The Role of Emotion-Triggered Impulsivity.

Authors:  Sheri L Johnson; Charles S Carver; Jordan A Tharp
Journal:  Suicide Life Threat Behav       Date:  2016-07-13

3.  Assessment Tools for Adult Bipolar Disorder.

Authors:  Christopher J Miller; Sheri L Johnson; Lori Eisner
Journal:  Clin Psychol (New York)       Date:  2009-06-01

4.  Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study.

Authors:  D Loldrup; M Langemark; H J Hansen; J Olesen; P Bech
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Clinical trial design in non-invasive brain stimulation psychiatric research.

Authors:  André Russowsky Brunoni; Felipe Fregni
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

6.  Satisfaction with treatment among patients with depressive and bipolar disorders.

Authors:  Lars Vedel Kessing; Hanne Vibe Hansen; Mirella Ruggeri; Per Bech
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-02-07       Impact factor: 4.328

7.  What about mental health after one year of COVID-19 pandemic? A comparison with the initial peak.

Authors:  Lorena García-Fernández; Verónica Romero-Ferreiro; Victoria Rodríguez; Miguel A Alvarez-Mon; Guillermo Lahera; Roberto Rodriguez-Jimenez
Journal:  J Psychiatr Res       Date:  2022-07-05       Impact factor: 5.250

8.  Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder.

Authors:  Christopher Baethge; Philipp Gruschka; Michael N Smolka; Anne Berghöfer; Tom Bschor; Bruno Müller-Oerlinghausen; Michael Bauer
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

9.  [11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging.

Authors:  Donald F Smith; Bo S Stork; Gregers Wegener; Mahmoud Ashkanian; Steen Jakobsen; Dirk Bender; Hélène Audrain; Karina H Vase; Søren B Hansen; Poul Videbech; Raben Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  2009-06-18       Impact factor: 4.530

10.  The Greek translation of the symptoms rating scale for depression and anxiety: preliminary results of the validation study.

Authors:  Konstantinos N Fountoulakis; Apostolos Iacovides; Soula Kleanthous; Stavros Samolis; Kyriakos Gougoulias; George St Kaprinis; Per Bech
Journal:  BMC Psychiatry       Date:  2003-12-10       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.